Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
IMG-7289 in Patients With Essential Thrombocythemia

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with essential thrombocythemia. This study investigates the following: The safety and tolerability of IMG-7289 The pharmacodynamic effect of IMG-7289

platelet count
interferon
thrombosis
thrombocytosis
  • 0 views
  • 06 Mar, 2021
  • 1 location
Hematology IMG-7289 LSD1 (Lysine-Specific Demethylase 1) Inhibitor Essential Thrombocythemia (ET) Ph 2

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

platelet count
interferon
neutrophil count
thrombocytosis
lysine
  • 0 views
  • 24 Jan, 2021
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

myeloproliferative/myelodysplastic disorders
myeloproliferative syndromes
myeloproliferative disorders
myeloproliferative disorder
myelofibrosis
  • 0 views
  • 22 Jan, 2021
  • 1 location
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit >48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4 weeks …

  • 0 views
  • 07 Mar, 2021
  • 2 locations
Tagraxofusp (SL-401) in Patients With CMML or MF

This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or myelofibrosis (MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), …

dysplasia
platelet count
neutrophil count
monocytosis
myelomonocytic leukemia
  • 145 views
  • 24 Jan, 2021
  • 13 locations
Molecular Biology of Polycythemia and Thrombocytosis

Our study is designed to characterize the clinical picture and genetic pattern of Polycythemia and Thrombocytosis. The purpose of this project is to find a gene and its mutation that causes these disorders. When this is accomplished, new therapies to control and eventually cure the disorder can be designed.

  • 5 views
  • 26 Jan, 2021
  • 1 location
Decitabine Venetoclax and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia

To determine the efficacy of the regimen, as defined by the rate of complete remission (CR) or CR with incomplete count recovery (CRi)

decitabine
hemolysis
leukemia
gilbert's syndrome
remission
  • 0 views
  • 07 Mar, 2021
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

lymphoid leukemia
t315i mutation
blast crisis
solid tumour
cancer
  • 23 views
  • 26 Jan, 2021
  • 32 locations
Venetoclax Ponatinib and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

This phase I/II trial studies the best dose of venetoclax when given together with ponatinib and dexamethasone and to see how well they work in treating participants with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia that has come back or does not respond to treatment. …

dexamethasone
lymphoid leukemia
hemolysis
leukemia
serum lipase
  • 55 views
  • 25 Jan, 2021
  • 1 location
Itacitinib Tacrolimus and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia Myelodysplastic Syndrome or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

This phase IIa trial studies the side effects of itacitinib when given together with standard treatment (tacrolimus and sirolimus), and to see how well it works in preventing graft-versus-host-disease (GVHD) in patients with acute leukemia, myelodysplastic syndrome or myelofibrosis who are undergoing reduced intensity conditioning donor stem cell transplantation. GVHD …

itacitinib
pulmonary function test
myeloablative conditioning
leukemia
ejection fraction
  • 0 views
  • 27 Jan, 2021
  • 1 location